"Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial" was originally created and published by Clinical Trials ...

A gut microbe could naturally regulate sugar cravings and blood sugar levels, offering a promising alternative to drugs like ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

About Oral Ecnoglutide (XW004): Glucagon-like peptide-1 (GLP-1 ... 1 peptide Ecnoglutide tablet XW004 (Phase I), and oral small molecule GLP-1 receptor agonist XW014 (Phase I).

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Harm from carbonated drinks, shallow focus insulin molecule stock videos & royalty-free footage This 3D animation illustrates glucagon, a peptide hormone secreted by the alpha cells of the pancreas.

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?